Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors
Journal for ImmunoTherapy of Cancer · 2024-09 · 12 (9) · e009128
DOI: 10.1136/jitc-2024-009128 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 28.09.2024. Verfasst von Young Kwang Chae und 15 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA chaelabmeeting@gmail.com. Hauptthemen laut MEDLINE: CTLA-4 Antigen, Desmoid Tumors. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH/NCI/NCTN, Bristol Myers Squibb Company.
Abstract (Originalsprache)
Background
Dual inhibition using anti-programmed death-1 (PD-1) and anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) checkpoint inhibitors has proven effective in many cancers. However, its efficacy in rare solid cancers remains unclear. Desmoid tumors are ultrarare soft-tissue tumors, traditionally treated with surgery. This study reviews the first results of using ipilimumab and nivolumab in the desmoid tumor cohort of the SWOG S1609 Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors (DART) trial.
Methods
DART is a prospective/open-label/multicenter (1,016 US sites)/multicohort phase II trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg intravenously every 2 weeks) that opened at 1,016 US sites. The primary endpoint included overall response rate (ORR) defined as confirmed complete (CR) and partial responses (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1. Secondary endpoints include progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR; stable disease (SD) ≥6 months plus CR and PR) and toxicity.
Results
Sixteen evaluable patients (median age: 37) with desmoid tumors and a median of 1.5 prior therapies (with no prior exposure to immunotherapy) were analyzed. The tumors varied in location (eight abdomen, three lower limb, two upper limb, two pelvis, and one neck). ORR was 18.8% (3/16; 3 confirmed PR): 40% regression (PFS 30+ months), 83% regression (PFS 16 months) and 71% regression (PFS 8.4 months). Seven additional patients (43.8%) had prolonged SD over 6 months (PFS: 16.5, 22.4+, 22.6, 30.1, 38.2+, 48.3+ and 60.7+ months). Overall CBR was 62.5% (10/16). Median PFS was 19.4 months, with 6-month PFS of 73% and 1-year PFS of 67%. All patients were alive at 1 year; median OS was not assessable, as 13 patients were alive at analysis. Common adverse events included fatigue, nausea and hypothyroidism, with 50% experiencing grade 3–4 events. There were no grade 5 events.
Conclusion
Treatment with ipilimumab and nivolumab in desmoid tumors yielded an ORR of 18.8% and a CBR of 62.5% with durable responses seen. This is the first prospective study exploring the efficacy of this combination in this rare disease. Ongoing studies aim to identify markers for response and resistance. Expanded trials are necessary. Trial registration number NCT02834013 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA chaelabmeeting@gmail.com.
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
- SWOG Statistics and Data Management Center, SWOG, Seattle, Washington, USA.
- University of California San Diego Moores Cancer Center, La Jolla, California, USA.
- The University of Kansas Cancer Center, Overland Park, Kansas, USA.
- Loma Linda University Cancer Center, Loma Linda, California, USA.
ORCID-Profile: Young Kwang Chae
Förderung
- NCI NIH HHS
- NIH/NCI/NCTN
- Bristol Myers Squibb Company
Zitieren
APA
Chae, Y. K., Othus, M., Patel, S., Powers, B., Hsueh, C. T., Govindarajan, R., Bucur, S., Kim, H. S., Chung, L. I., McLeod, C., Chen, H. X., Sharon, E., Streicher, H., Ryan, C. W., Blanke, C., & Kurzrock, R. (2024). Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors. Journal for ImmunoTherapy of Cancer, 12(9), e009128. https://doi.org/10.1136/jitc-2024-009128
Vancouver
Chae YK, Othus M, Patel S, Powers B, Hsueh CT, Govindarajan R, et al. Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors. Journal for ImmunoTherapy of Cancer. 2024;12(9):e009128. doi:10.1136/jitc-2024-009128
BibTeX
@article{Chae2024,
author = {Chae, Young Kwang and Othus, Megan and Patel, Sandip and Powers, Benjamin and Hsueh, Chung-Tsen and Govindarajan, Rangaswamy and Bucur, Silvana and Kim, Hye Sung and Chung, Liam Il-Young and McLeod, Christine and Chen, Helen X and Sharon, Elad and Streicher, Howard and Ryan, Christopher W and Blanke, Charles and Kurzrock, Razelle},
title = {Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {9},
pages = {e009128},
doi = {10.1136/jitc-2024-009128}
}
EUVIMED